<DOC>
	<DOCNO>NCT01288170</DOCNO>
	<brief_summary>Cystic fibrosis ( CF ) genetic disease characterize mutation CFTR ( Cystic Fibrosis Transmembrane conductance Regulator ) gene . Mortality morbidity mostly related respiratory affection appear early neonate . The constant improvement symptomatic treatment care strategy allow CF patient ' life expectancy increase last decade . Vital prognostic relate bronchopulmonary infection . 39 % CF patient 18 year old 70 % adult CF patient chronically infect Pseudomonas aeruginosa . Elevated concentration tobramycin broncho secretion , 1000 time MIC , obtain inhaled administration tobramycin active vitro resistant Pseudomonas aeruginosa . Study hypotheses : Regarding literature data vitro study , administration Nebcinal® 150mg/3ml administer twice day Aeroneb® Idehaler® pocket® would deliver quantity antibiotic lung plasma Tobi® 300mg/5ml administer twice day Pari® LC Plus® child adult patient CF . Primary objective : To compare plasma concentration inhalation Nebcinal® 150mg/3ml administer Aeroneb® Idehaler pocket® Tobi® 300 mg/5ml administer Pari LC Plus®</brief_summary>
	<brief_title>Pharmacokinetic Bioequivalence Study Nebcinal® 150mg/3ml Administered Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered Pari LC Plus®</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Adults child age 6 year old Male female Patients cystic fibrosis ( positive sudoral test , Cl &gt; 60 mmol/L ) Followed CRCM ( CF care centre ) FEV1 ≥40 % Informed consent collect adult parent legal guardian child . Affiliation National Health Insurance program ( Sécurité sociale ) . renal insufficiency define creatinine clearance level superior 2 mg/dl recent pneumothorax , emphysema , punction recent pleural biopsy , recent haemoptysis superior 60 ml within 30 day prior randomization Acute pulmonary exacerbation pathology , accord conference consensus ( 2002 ) , evaluate : Cough increase , Sputum increase , Decrease tolerance effort , Loss weight , lack appetite , Deterioration respiratory function , Medical history intolerance , toxicity allergy tobramycine , hypersensitivity aminoside</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>cystic fibrosis , bioequivalence , pharmacokinetic , sputum , plasma</keyword>
</DOC>